

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All cancers

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
All cases			N	%	N	%	N	%	N	%	N	%	N	%	
Both sexes	All cases		12596	995	7.9	5840	46.4	569	4.5	8970	71.3	648	5.2	840	6.7
	Age at baseline	<18	3606	395	11.0	1758	48.8	58	1.6	2791	77.4	347	9.6	442	12.3
		18-19	1112	94	8.5	572	51.5	22	2.0	877	78.9	77	6.9	82	7.4
		20-24	2665	222	8.3	1304	49.0	115	4.3	2008	75.4	132	5.0	174	6.5
		25-29	2406	175	7.3	1136	47.3	160	6.7	1639	68.2	62	2.6	93	3.9
		30-34	1697	90	5.3	694	41.0	135	8.0	1065	62.9	26	1.5	42	2.5
		35+	1110	19	1.7	376	34.1	79	7.2	590	53.5	4	0.4	7	0.6
	Years since diagnosis	5-9	1932	301	15.6	990	51.3	131	6.8	1483	76.8	189	9.8	395	20.5
		10-14	4649	480	10.3	2195	47.3	244	5.3	3291	70.9	309	6.7	360	7.8
		15-19	3456	162	4.7	1594	46.2	121	3.5	2513	72.8	135	3.9	75	2.2
		20+	2559	52	2.0	1061	41.6	73	2.9	1683	66.0	15	0.6	10	0.4
	Age at diagnosis	<1	882	30	3.4	85	9.6	10	1.1	447	50.7	43	4.9	41	4.7
		1-4	4186	337	8.1	2294	54.8	36	0.9	3462	82.7	313	7.5	314	7.5
		5-9	2777	250	9.0	1502	54.2	70	2.5	2143	77.3	152	5.5	197	7.1
		10-14	2531	212	8.4	1162	46.0	185	7.3	1700	67.3	97	3.8	155	6.1
		15-20	2220	166	7.5	797	36.0	268	12.1	1218	55.1	43	1.9	133	6.0
	Treatment	Chemotherapy, no radiation	3091	261	8.4	1521	49.2	83	2.7	2590	83.8	146	4.7	206	6.7
		Chemotherapy and radiation	7024	734	10.4	4303	61.3	486	6.9	6361	90.6	502	7.1	633	9.0
Males	All cases		6650	578	8.7	3213	48.4	327	4.9	4771	71.9	360	5.4	474	7.1
	Age at baseline	<18	1919	224	11.7	974	50.8	43	2.2	1497	78.1	193	10.1	257	13.4
		18-19	606	62	10.2	333	55.0	18	3.0	481	79.4	43	7.1	49	8.1
		20-24	1380	117	8.5	690	50.1	70	5.1	1035	75.1	67	4.9	88	6.4
		25-29	1331	108	8.1	670	50.4	89	6.7	915	68.8	38	2.9	54	4.1
		30-34	886	59	6.7	364	41.1	74	8.4	553	62.5	17	1.9	25	2.8
		35+	528	8	1.5	182	34.7	33	6.3	290	55.3	2	0.4	1	0.2
	Years since diagnosis	5-9	1073	171	15.9	584	54.4	81	7.5	833	77.6	108	10.1	226	21.1
		10-14	2495	279	11.2	1238	49.7	144	5.8	1786	71.6	173	6.9	206	8.3
		15-19	1764	95	5.4	835	47.4	65	3.7	1288	73.1	70	4.0	36	2.0
		20+	1318	33	2.5	556	42.3	37	2.8	864	65.8	9	0.7	6	0.5
	Age at diagnosis	<1	446	15	3.4	35	7.9	4	0.9	217	48.8	22	4.9	19	4.3
		1-4	2174	198	9.1	1226	56.4	25	1.1	1803	82.9	174	8.0	189	8.7
		5-9	1548	152	9.8	865	56.0	58	3.8	1193	77.2	80	5.2	109	7.1
		10-14	1315	108	8.2	638	48.6	100	7.6	896	68.3	58	4.4	82	6.3
		15-20	1167	105	9.0	449	38.6	140	12.0	662	56.9	26	2.2	75	6.4

	Treatment	Chemotherapy, no radiation	1570	123	7.8	774	49.3	45	2.9	1308	83.3	74	4.7	104	6.6
		Chemotherapy and radiation	3810	455	11.9	2428	63.7	282	7.4	3451	90.6	286	7.5	369	9.7
Females	All cases		5946	417	7.0	2627	44.2	242	4.1	4199	70.7	288	4.9	366	6.2
	Age at baseline	<18	1687	171	10.1	784	46.5	15	0.9	1294	76.7	154	9.1	185	11.0
		18-19	506	32	6.3	239	47.3	4	0.8	396	78.4	34	6.7	33	6.5
		20-24	1285	105	8.2	614	47.8	45	3.5	973	75.7	65	5.1	86	6.7
		25-29	1075	67	6.2	466	43.4	71	6.6	724	67.4	24	2.2	39	3.6
		30-34	811	31	3.8	330	40.8	61	7.5	512	63.3	9	1.1	17	2.1
		35+	582	11	1.9	194	33.5	46	7.9	300	51.8	2	0.3	6	1.0
	Years since diagnosis	5-9	859	130	15.2	406	47.3	50	5.8	650	75.8	81	9.4	169	19.7
		10-14	2154	201	9.3	957	44.5	100	4.6	1505	69.9	136	6.3	154	7.2
		15-19	1692	67	4.0	759	44.9	56	3.3	1225	72.5	65	3.8	39	2.3
		20+	1241	19	1.5	505	40.8	36	2.9	819	66.2	6	0.5	4	0.3
	Age at diagnosis	<1	436	15	3.4	50	11.5	6	1.4	230	52.8	21	4.8	22	5.0
		1-4	2012	139	6.9	1068	53.1	11	0.5	1659	82.5	139	6.9	125	6.2
		5-9	1229	98	8.0	637	51.9	12	1.0	950	77.4	72	5.9	88	7.2
		10-14	1216	104	8.6	524	43.2	85	7.0	804	66.2	39	3.2	73	6.0
		15-20	1053	61	5.8	348	33.2	128	12.2	556	53.0	17	1.6	58	5.5
	Treatment	Chemotherapy, no radiation	1521	138	9.1	747	49.1	38	2.5	1282	84.3	72	4.7	102	6.7
		Chemotherapy and radiation	3214	279	8.7	1875	58.3	204	6.3	2910	90.5	216	6.7	264	8.2

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All leukemias

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		4276	584	13.7	3975	93.0	24	0.6	4084	95.5	483	11.3	500	11.7
	Age at baseline	<18	1636	310	18.9	1522	93.0	11	0.7	1573	96.1	253	15.5	292	17.8
		18-19	503	62	12.3	466	92.6	3	0.6	479	95.2	57	11.3	54	10.7
		20-24	999	119	11.9	936	93.7	4	0.4	959	96.0	108	10.8	90	9.0
		25-29	714	75	10.5	660	92.4	5	0.7	670	93.8	48	6.7	49	6.9
		30-34	309	14	4.5	282	91.3	1	0.3	292	94.5	14	4.5	13	4.2
		35+	115	4	3.5	109	94.8	.	.	111	96.5	3	2.6	2	1.7
	Years since diagnosis	5-9	784	198	25.3	707	90.2	5	0.6	734	93.6	136	17.3	202	25.8
		10-14	1679	275	16.4	1555	92.6	8	0.5	1599	95.2	241	14.4	235	14.0
		15-19	1096	80	7.3	1022	93.2	8	0.7	1048	95.6	95	8.7	56	5.1
		20+	717	31	4.3	691	96.4	3	0.4	703	98.0	11	1.5	7	1.0
	Age at diagnosis	<1	87	16	18.4	62	71.3	1	1.1	77	88.5	14	16.1	26	29.9
		1-4	2204	271	12.3	2078	94.3	13	0.6	2130	96.6	250	11.3	232	10.5
		5-9	1109	162	14.6	1061	95.7	8	0.7	1077	97.1	118	10.6	114	10.3
		10-14	592	95	16.0	532	89.9	2	0.3	551	93.1	72	12.2	81	13.7
		15-20	284	40	14.1	242	85.2	.	.	249	87.7	29	10.2	47	16.5
	Treatment	Chemotherapy, no radiation	1302	145	11.1	1160	89.1	7	0.5	1229	94.4	89	6.8	154	11.8
		Chemotherapy and radiation	2955	439	14.9	2800	94.8	17	0.6	2839	96.1	394	13.3	345	11.7
Males	All cases		2221	332	14.9	2068	93.1	16	0.7	2117	95.3	269	12.1	274	12.3
	Age at baseline	<18	882	176	20.0	819	92.9	8	0.9	844	95.7	147	16.7	165	18.7
		18-19	268	40	14.9	251	93.7	3	1.1	257	95.9	29	10.8	33	12.3
		20-24	485	58	12.0	455	93.8	1	0.2	465	95.9	52	10.7	43	8.9
		25-29	383	47	12.3	356	93.0	3	0.8	359	93.7	30	7.8	25	6.5
		30-34	153	9	5.9	138	90.2	1	0.7	144	94.1	9	5.9	8	5.2
		35+	50	2	4.0	49	98.0	.	.	48	96.0	2	4.0	.	.
	Years since diagnosis	5-9	441	113	25.6	398	90.2	4	0.9	412	93.4	78	17.7	113	25.6
		10-14	888	152	17.1	823	92.7	5	0.6	847	95.4	136	15.3	131	14.8
		15-19	534	48	9.0	501	93.8	5	0.9	509	95.3	48	9.0	25	4.7
		20+	358	19	5.3	346	96.6	2	0.6	349	97.5	7	2.0	5	1.4
	Age at diagnosis	<1	38	7	18.4	26	68.4	.	.	33	86.8	8	21.1	12	31.6
		1-4	1149	155	13.5	1085	94.4	8	0.7	1107	96.3	143	12.4	138	12.0
		5-9	583	101	17.3	557	95.5	7	1.2	565	96.9	62	10.6	59	10.1

		10-14	278	42	15.1	253	91.0	1	0.4	259	93.2	38	13.7	38	13.7
		15-20	173	27	15.6	147	85.0	.	.	153	88.4	18	10.4	27	15.6
	Treatment	Chemotherapy, no radiation	598	62	10.4	533	89.1	4	0.7	558	93.3	42	7.0	71	11.9
		Chemotherapy and radiation	1611	270	16.8	1525	94.7	12	0.7	1549	96.2	227	14.1	202	12.5
Females	All cases		2055	252	12.3	1907	92.8	8	0.4	1967	95.7	214	10.4	226	11.0
	Age at baseline	<18	754	134	17.8	703	93.2	3	0.4	729	96.7	106	14.1	127	16.8
		18-19	235	22	9.4	215	91.5	.	.	222	94.5	28	11.9	21	8.9
		20-24	514	61	11.9	481	93.6	3	0.6	494	96.1	56	10.9	47	9.1
		25-29	331	28	8.5	304	91.8	2	0.6	311	94.0	18	5.4	24	7.3
		30-34	156	5	3.2	144	92.3	.	.	148	94.9	5	3.2	5	3.2
		35+	65	2	3.1	60	92.3	.	.	63	96.9	1	1.5	2	3.1
	Years since diagnosis	5-9	343	85	24.8	309	90.1	1	0.3	322	93.9	58	16.9	89	25.9
		10-14	791	123	15.5	732	92.5	3	0.4	752	95.1	105	13.3	104	13.1
		15-19	562	32	5.7	521	92.7	3	0.5	539	95.9	47	8.4	31	5.5
		20+	359	12	3.3	345	96.1	1	0.3	354	98.6	4	1.1	2	0.6
	Age at diagnosis	<1	49	9	18.4	36	73.5	1	2.0	44	89.8	6	12.2	14	28.6
		1-4	1055	116	11.0	993	94.1	5	0.5	1023	97.0	107	10.1	94	8.9
		5-9	526	61	11.6	504	95.8	1	0.2	512	97.3	56	10.6	55	10.5
		10-14	314	53	16.9	279	88.9	1	0.3	292	93.0	34	10.8	43	13.7
		15-20	111	13	11.7	95	85.6	.	.	96	86.5	11	9.9	20	18.0
	Treatment	Chemotherapy, no radiation	704	83	11.8	627	89.1	3	0.4	671	95.3	47	6.7	83	11.8
		Chemotherapy and radiation	1344	169	12.6	1275	94.9	5	0.4	1290	96.0	167	12.4	143	10.6

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: ALL

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		3657	472	12.9	3570	97.6	21	0.6	3610	98.7	463	12.7	352	9.6
	Age at baseline	<18	1428	252	17.6	1399	98.0	10	0.7	1410	98.7	244	17.1	210	14.7
		18-19	436	50	11.5	428	98.2	3	0.7	431	98.9	54	12.4	37	8.5
		20-24	863	95	11.0	837	97.0	4	0.5	850	98.5	102	11.8	66	7.6
		25-29	600	64	10.7	585	97.5	3	0.5	592	98.7	46	7.7	31	5.2
		30-34	248	8	3.2	240	96.8	1	0.4	246	99.2	14	5.6	7	2.8
		35+	82	3	3.7	81	98.8	.	.	81	98.8	3	3.7	1	1.2
	Years since diagnosis	5-9	649	158	24.3	635	97.8	5	0.8	641	98.8	126	19.4	136	21.0
		10-14	1456	220	15.1	1424	97.8	7	0.5	1440	98.9	233	16.0	169	11.6
		15-19	937	67	7.2	909	97.0	7	0.7	920	98.2	94	10.0	43	4.6
		20+	615	27	4.4	602	97.9	2	0.3	609	99.0	10	1.6	4	0.7
	Age at diagnosis	<1	51	12	23.5	50	98.0	1	2.0	50	98.0	12	23.5	9	17.6
		1-4	1949	223	11.4	1902	97.6	11	0.6	1924	98.7	243	12.5	173	8.9
		5-9	998	138	13.8	977	97.9	8	0.8	983	98.5	113	11.3	89	8.9
		10-14	464	69	14.9	452	97.4	1	0.2	460	99.1	68	14.7	53	11.4
		15-20	195	30	15.4	189	96.9	.	.	193	99.0	27	13.8	28	14.4
	Treatment	Chemotherapy, no radiation	1069	101	9.4	1040	97.3	6	0.6	1056	98.8	82	7.7	70	6.5
		Chemotherapy and radiation	2573	371	14.4	2516	97.8	15	0.6	2539	98.7	381	14.8	281	10.9
Males	All cases		1914	273	14.3	1868	97.6	15	0.8	1887	98.6	254	13.3	191	10.0
	Age at baseline	<18	774	143	18.5	756	97.7	7	0.9	763	98.6	141	18.2	120	15.5
		18-19	238	35	14.7	234	98.3	3	1.3	236	99.2	27	11.3	22	9.2
		20-24	418	48	11.5	406	97.1	1	0.2	412	98.6	47	11.2	30	7.2
		25-29	326	41	12.6	319	97.9	3	0.9	320	98.2	28	8.6	14	4.3
		30-34	121	5	4.1	116	95.9	1	0.8	120	99.2	9	7.4	5	4.1
		35+	37	1	2.7	37	.	.	.	36	97.3	2	5.4	.	.
	Years since diagnosis	5-9	366	94	25.7	356	97.3	4	1.1	362	98.9	72	19.7	76	20.8
		10-14	780	124	15.9	762	97.7	4	0.5	771	98.8	129	16.5	93	11.9
		15-19	457	39	8.5	444	97.2	5	1.1	447	97.8	47	10.3	20	4.4
		20+	311	16	5.1	306	98.4	2	0.6	307	98.7	6	1.9	2	0.6
	Age at diagnosis	<1	24	5	20.8	23	95.8	.	.	24	.	7	29.2	5	20.8
		1-4	1023	129	12.6	1001	97.8	7	0.7	1009	98.6	137	13.4	101	9.9
		5-9	525	86	16.4	514	97.9	7	1.3	517	98.5	59	11.2	46	8.8
		10-14	220	32	14.5	214	97.3	1	0.5	217	98.6	34	15.5	24	10.9

		15-20	122	21	17.2	116	95.1	.	.	120	98.4	17	13.9	15	12.3
	Treatment	Chemotherapy, no radiation	495	44	8.9	481	97.2	3	0.6	488	98.6	37	7.5	31	6.3
		Chemotherapy and radiation	1410	229	16.2	1378	97.7	12	0.9	1390	98.6	217	15.4	159	11.3
Females	All cases		1743	199	11.4	1702	97.6	6	0.3	1723	98.9	209	12.0	161	9.2
	Age at baseline	<18	654	109	16.7	643	98.3	3	0.5	647	98.9	103	15.7	90	13.8
		18-19	198	15	7.6	194	98.0	.	.	195	98.5	27	13.6	15	7.6
		20-24	445	47	10.6	431	96.9	3	0.7	438	98.4	55	12.4	36	8.1
		25-29	274	23	8.4	266	97.1	.	.	272	99.3	18	6.6	17	6.2
		30-34	127	3	2.4	124	97.6	.	.	126	99.2	5	3.9	2	1.6
		35+	45	2	4.4	44	97.8	.	.	45	.	1	2.2	1	2.2
	Years since diagnosis	5-9	283	64	22.6	279	98.6	1	0.4	279	98.6	54	19.1	60	21.2
		10-14	676	96	14.2	662	97.9	3	0.4	669	99.0	104	15.4	76	11.2
		15-19	480	28	5.8	465	96.9	2	0.4	473	98.5	47	9.8	23	4.8
		20+	304	11	3.6	296	97.4	.	.	302	99.3	4	1.3	2	0.7
	Age at diagnosis	<1	27	7	25.9	27	.	1	3.7	26	96.3	5	18.5	4	14.8
		1-4	926	94	10.2	901	97.3	4	0.4	915	98.8	106	11.4	72	7.8
		5-9	473	52	11.0	463	97.9	1	0.2	466	98.5	54	11.4	43	9.1
		10-14	244	37	15.2	238	97.5	.	.	243	99.6	34	13.9	29	11.9
		15-20	73	9	12.3	73	.	.	.	73	.	10	13.7	13	17.8
	Treatment	Chemotherapy, no radiation	574	57	9.9	559	97.4	3	0.5	568	99.0	45	7.8	39	6.8
		Chemotherapy and radiation	1163	142	12.2	1138	97.9	3	0.3	1149	98.8	164	14.1	122	10.5

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: AML

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		322	73	22.7	151	46.9	1	0.3	227	70.5	7	2.2	128	39.8
	Age at baseline	<18	103	36	35.0	33	32.0	1	1.0	74	71.8	3	2.9	67	65.0
		18-19	40	10	25.0	16	40.0	.	.	27	67.5	2	5.0	17	42.5
		20-24	62	12	19.4	32	51.6	.	.	43	69.4	2	3.2	22	35.5
		25-29	66	9	13.6	34	51.5	.	.	41	62.1	.	.	16	24.2
		30-34	35	5	14.3	23	65.7	.	.	29	82.9	.	.	5	14.3
		35+	16	1	6.3	13	81.3	.	.	13	81.3	.	.	1	6.3
	Years since diagnosis	5-9	70	30	42.9	23	32.9	.	.	45	64.3	5	7.1	58	82.9
		10-14	127	31	24.4	46	36.2	1	0.8	84	66.1	2	1.6	56	44.1
		15-19	86	10	11.6	52	60.5	.	.	63	73.3	.	.	13	15.1
		20+	39	2	5.1	30	76.9	.	.	35	89.7	.	.	1	2.6
	Age at diagnosis	<1	28	4	14.3	9	32.1	.	.	22	78.6	2	7.1	15	53.6
		1-4	106	30	28.3	41	38.7	1	0.9	75	70.8	1	0.9	48	45.3
		5-9	57	11	19.3	33	57.9	.	.	43	75.4	3	5.3	21	36.8
		10-14	74	21	28.4	35	47.3	.	.	49	66.2	.	.	26	35.1
		15-20	57	7	12.3	33	57.9	.	.	38	66.7	1	1.8	18	31.6
	Treatment	Chemotherapy, no radiation	166	36	21.7	68	41.0	1	0.6	121	72.9	5	3.0	78	47.0
		Chemotherapy and radiation	155	37	23.9	82	52.9	.	.	105	67.7	2	1.3	50	32.3
Males	All cases		153	34	22.2	70	45.8	1	0.7	102	66.7	4	2.6	71	46.4
	Age at baseline	<18	52	18	34.6	15	28.8	1	1.9	32	61.5	1	1.9	36	69.2
		18-19	19	4	21.1	7	36.8	.	.	12	63.2	1	5.3	11	57.9
		20-24	32	3	9.4	18	56.3	.	.	22	68.8	2	6.3	12	37.5
		25-29	27	5	18.5	13	48.1	.	.	17	63.0	.	.	10	37.0
		30-34	18	3	16.7	12	66.7	.	.	15	83.3	.	.	2	11.1
		35+	5	1	20.0	5	.	.	.	4	80.0
	Years since diagnosis	5-9	41	13	31.7	15	36.6	.	.	22	53.7	3	7.3	34	82.9
		10-14	58	13	22.4	17	29.3	1	1.7	38	65.5	1	1.7	31	53.4
		15-19	39	6	15.4	26	66.7	.	.	29	74.4	.	.	5	12.8
		20+	15	2	13.3	12	80.0	.	.	13	86.7	.	.	1	6.7
	Age at diagnosis	<1	11	2	18.2	2	18.2	.	.	7	63.6	1	9.1	7	63.6
		1-4	52	14	26.9	19	36.5	1	1.9	33	63.5	.	.	28	53.8
		5-9	29	6	20.7	16	55.2	.	.	21	72.4	2	6.9	11	37.9
		10-14	27	7	25.9	14	51.9	.	.	18	66.7	.	.	13	48.1

		15-20	34	5	14.7	19	55.9	.	.	23	67.6	1	2.9	12	35.3
	Treatment	Chemotherapy, no radiation	71	13	18.3	28	39.4	1	1.4	47	66.2	3	4.2	37	52.1
		Chemotherapy and radiation	81	21	25.9	41	50.6	.	.	54	66.7	1	1.2	34	42.0
Females	All cases		169	39	23.1	81	47.9	.	.	125	74.0	3	1.8	57	33.7
	Age at baseline	<18	51	18	35.3	18	35.3	.	.	42	82.4	2	3.9	31	60.8
		18-19	21	6	28.6	9	42.9	.	.	15	71.4	1	4.8	6	28.6
		20-24	30	9	30.0	14	46.7	.	.	21	70.0	.	.	10	33.3
		25-29	39	4	10.3	21	53.8	.	.	24	61.5	.	.	6	15.4
		30-34	17	2	11.8	11	64.7	.	.	14	82.4	.	.	3	17.6
		35+	11	.	.	8	72.7	.	.	9	81.8	.	.	1	9.1
	Years since diagnosis	5-9	29	17	58.6	8	27.6	.	.	23	79.3	2	6.9	24	82.8
		10-14	69	18	26.1	29	42.0	.	.	46	66.7	1	1.4	25	36.2
		15-19	47	4	8.5	26	55.3	.	.	34	72.3	.	.	8	17.0
		20+	24	.	.	18	75.0	.	.	22	91.7
	Age at diagnosis	<1	17	2	11.8	7	41.2	.	.	15	88.2	1	5.9	8	47.1
		1-4	54	16	29.6	22	40.7	.	.	42	77.8	1	1.9	20	37.0
		5-9	28	5	17.9	17	60.7	.	.	22	78.6	1	3.6	10	35.7
		10-14	47	14	29.8	21	44.7	.	.	31	66.0	.	.	13	27.7
		15-20	23	2	8.7	14	60.9	.	.	15	65.2	.	.	6	26.1
	Treatment	Chemotherapy, no radiation	95	23	24.2	40	42.1	.	.	74	77.9	2	2.1	41	43.2
		Chemotherapy and radiation	74	16	21.6	41	55.4	.	.	51	68.9	1	1.4	16	21.6

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All CNS

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1663	116	7.0	157	9.5	3	0.2	357	21.6	11	0.7	48	2.9
	Age at baseline	<18	503	45	8.9	64	12.7	1	0.2	164	32.6	3	0.6	32	6.4
		18-19	142	13	9.2	13	9.2	.	.	33	23.4	1	0.7	3	2.1
		20-24	381	23	6.1	40	10.5	.	.	75	19.7	5	1.3	11	2.9
		25-29	339	26	7.7	32	9.5	2	0.6	61	18.2	1	0.3	2	0.6
		30-34	209	8	3.8	8	3.8	.	.	22	10.5	1	0.5	.	.
		35+	89	1	1.1	2	2.3
	Years since diagnosis	5-9	298	34	11.4	50	16.8	.	.	110	36.9	4	1.3	33	11.1
		10-14	663	43	6.5	45	6.8	2	0.3	133	20.1	.	.	15	2.3
		15-19	408	31	7.7	52	12.8	1	0.2	81	20.0	6	1.5	.	.
		20+	294	8	2.7	10	3.4	.	.	33	11.3	1	0.3	.	.
	Age at diagnosis	<1	87	5	5.7	11	12.6	.	.	33	37.9	1	1.1	6	6.9
		1-4	485	36	7.4	47	9.7	.	.	118	24.3	5	1.0	13	2.7
		5-9	496	44	8.9	59	12.0	1	0.2	115	23.3	3	0.6	13	2.6
		10-14	412	23	5.6	31	7.6	2	0.5	70	17.1	2	0.5	10	2.4
		15-20	183	8	4.4	9	5.0	.	.	21	11.6	.	.	6	3.3
	Treatment	Chemotherapy, no radiation	29	4	13.8	7	24.1	.	.	26	89.7	.	.	2	6.9
		Chemotherapy and radiation	472	112	23.7	150	31.8	3	0.6	331	70.1	11	2.3	46	9.7
Males	All cases		912	72	7.9	93	10.3	3	0.3	217	23.9	6	0.7	29	3.2
	Age at baseline	<18	275	29	10.5	39	14.2	1	0.4	100	36.4	1	0.4	21	7.6
		18-19	79	7	8.9	6	7.6	.	.	17	21.5	1	1.3	1	1.3
		20-24	203	14	6.9	25	12.4	.	.	48	23.8	3	1.5	6	3.0
		25-29	192	19	10.0	19	10.0	2	1.1	39	20.5	1	0.5	1	0.5
		30-34	115	2	1.7	4	3.5	.	.	11	9.6
		35+	48	1	2.2	2	4.3
	Years since diagnosis	5-9	169	20	11.8	31	18.3	.	.	66	39.1	2	1.2	19	11.2
		10-14	361	28	7.8	33	9.2	2	0.6	88	24.4	.	.	10	2.8
		15-19	226	18	8.0	26	11.6	1	0.4	46	20.5	4	1.8	.	.
		20+	156	6	3.9	3	1.9	.	.	17	11.0
	Age at diagnosis	<1	51	5	9.8	7	13.7	.	.	22	43.1	.	.	4	7.8
		1-4	255	24	9.4	25	9.8	.	.	64	25.1	3	1.2	9	3.5
		5-9	275	25	9.2	34	12.5	1	0.4	73	26.7	2	0.7	7	2.6
		10-14	228	16	7.0	21	9.3	2	0.9	46	20.3	1	0.4	6	2.6

		15-20	103	2	2.0	6	5.9	.	.	12	11.9	.	.	3	3.0
	Treatment	Chemotherapy, no radiation	16	3	18.8	3	18.8	.	.	14	87.5	.	.	1	6.3
		Chemotherapy and radiation	284	69	24.3	90	31.7	3	1.1	203	71.5	6	2.1	28	9.9
Females	All cases		751	44	5.9	64	8.5	.	.	140	18.7	5	0.7	19	2.5
	Age at baseline	<18	228	16	7.0	25	11.0	.	.	64	28.1	2	0.9	11	4.8
		18-19	63	6	9.7	7	11.3	.	.	16	25.8	.	.	2	3.2
		20-24	178	9	5.1	15	8.4	.	.	27	15.2	2	1.1	5	2.8
		25-29	147	7	4.8	13	8.9	.	.	22	15.1	.	.	1	0.7
		30-34	94	6	6.4	4	4.3	.	.	11	11.7	1	1.1	.	.
		35+	41
	Years since diagnosis	5-9	129	14	10.9	19	14.7	.	.	44	34.1	2	1.6	14	10.9
		10-14	302	15	5.0	12	4.0	.	.	45	15.0	.	.	5	1.7
		15-19	182	13	7.2	26	14.4	.	.	35	19.3	2	1.1	.	.
		20+	138	2	1.4	7	5.1	.	.	16	11.6	1	0.7	.	.
	Age at diagnosis	<1	36	.	.	4	11.1	.	.	11	30.6	1	2.8	2	5.6
		1-4	230	12	5.2	22	9.6	.	.	54	23.5	2	0.9	4	1.7
		5-9	221	19	8.6	25	11.4	.	.	42	19.1	1	0.5	6	2.7
		10-14	184	7	3.8	10	5.5	.	.	24	13.1	1	0.5	4	2.2
		15-20	80	6	7.5	3	3.8	.	.	9	11.3	.	.	3	3.8
	Treatment	Chemotherapy, no radiation	13	1	7.7	4	30.8	.	.	12	92.3	.	.	1	7.7
		Chemotherapy and radiation	188	43	22.9	60	31.9	.	.	128	68.1	5	2.7	18	9.6

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Astrocytomas

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1055	41	3.9	45	4.3	1	0.1	133	12.7	7	0.7	11	1.0
	Age at baseline	<18	305	19	6.2	22	7.2	1	0.3	64	21.0	2	0.7	6	2.0
		18-19	89	3	3.4	4	4.5	.	.	15	16.9	.	.	1	1.1
		20-24	247	8	3.3	15	6.1	.	.	25	10.2	3	1.2	3	1.2
		25-29	217	8	3.7	1	0.5	.	.	16	7.4	1	0.5	1	0.5
		30-34	135	3	2.2	3	2.2	.	.	12	8.9	1	0.7	.	.
		35+	62	1	1.6
	Years since diagnosis	5-9	164	11	6.7	16	9.8	.	.	35	21.3	2	1.2	8	4.9
		10-14	427	20	4.7	14	3.3	1	0.2	60	14.1	.	.	3	0.7
		15-19	247	9	3.7	12	4.9	.	.	22	8.9	4	1.6	.	.
		20+	217	1	0.5	3	1.4	.	.	16	7.4	1	0.5	.	.
	Age at diagnosis	<1	62	4	6.5	8	12.9	.	.	20	32.3	1	1.6	4	6.5
		1-4	325	13	4.0	14	4.3	.	.	45	13.8	2	0.6	1	0.3
		5-9	295	12	4.1	14	4.8	1	0.3	35	11.9	3	1.0	1	0.3
		10-14	262	8	3.1	8	3.1	.	.	26	10.0	1	0.4	3	1.1
		15-20	111	4	3.6	1	0.9	.	.	7	6.4	.	.	2	1.8
	Treatment	Chemotherapy, no radiation	17	3	17.6	4	23.5	.	.	14	82.4	.	.	1	5.9
		Chemotherapy and radiation	200	38	19.0	41	20.5	1	0.5	119	59.5	7	3.5	10	5.0
Males	All cases		561	24	4.3	26	4.7	1	0.2	79	14.2	3	0.5	6	1.1
	Age at baseline	<18	161	12	7.5	15	9.3	1	0.6	39	24.2	.	.	4	2.5
		18-19	51	1	2.0	2	3.9	.	.	8	15.7
		20-24	121	4	3.3	8	6.7	.	.	15	12.5	2	1.7	2	1.7
		25-29	128	7	5.6	1	0.8	.	.	12	9.5	1	0.8	.	.
		30-34	68	4	5.9
		35+	32	1	3.2
	Years since diagnosis	5-9	90	4	4.4	9	10.0	.	.	19	21.1	.	.	4	4.4
		10-14	230	15	6.6	12	5.2	1	0.4	44	19.2	.	.	2	0.9
		15-19	127	4	3.2	5	4.0	.	.	8	6.3	3	2.4	.	.
		20+	114	1	0.9	8	7.1
	Age at diagnosis	<1	33	4	12.1	6	18.2	.	.	12	36.4	.	.	3	9.1
		1-4	169	9	5.3	8	4.7	.	.	23	13.6	1	0.6	1	0.6
		5-9	158	6	3.8	7	4.5	1	0.6	25	16.0	2	1.3	.	.

		10-14	140	4	2.9	5	3.6	.	.	16	11.5	.	.	1	0.7
		15-20	61	1	1.7	3	5.0	.	.	1	1.7
	Treatment	Chemotherapy, no radiation	8	2	25.0	2	25.0	.	.	6	75.0	.	.	1	12.5
		Chemotherapy and radiation	122	22	18.0	24	19.7	1	0.8	73	59.8	3	2.5	5	4.1
Females	All cases		494	17	3.4	19	3.8	.	.	54	10.9	4	0.8	5	1.0
	Age at baseline	<18	144	7	4.9	7	4.9	.	.	25	17.4	2	1.4	2	1.4
		18-19	38	2	5.3	2	5.3	.	.	7	18.4	.	.	1	2.6
		20-24	126	4	3.2	7	5.6	.	.	10	7.9	1	0.8	1	0.8
		25-29	89	1	1.1	4	4.5	.	.	1	1.1
		30-34	67	3	4.5	3	4.5	.	.	8	11.9	1	1.5	.	.
		35+	30
	Years since diagnosis	5-9	74	7	9.5	7	9.5	.	.	16	21.6	2	2.7	4	5.4
		10-14	197	5	2.5	2	1.0	.	.	16	8.1	.	.	1	0.5
		15-19	120	5	4.2	7	5.8	.	.	14	11.7	1	0.8	.	.
		20+	103	.	.	3	2.9	.	.	8	7.8	1	1.0	.	.
	Age at diagnosis	<1	29	.	.	2	6.9	.	.	8	27.6	1	3.4	1	3.4
		1-4	156	4	2.6	6	3.8	.	.	22	14.1	1	0.6	.	.
		5-9	137	6	4.4	7	5.1	.	.	10	7.3	1	0.7	1	0.7
		10-14	122	4	3.3	3	2.5	.	.	10	8.2	1	0.8	2	1.6
		15-20	50	3	6.0	1	2.0	.	.	4	8.0	.	.	1	2.0
	Treatment	Chemotherapy, no radiation	9	1	11.1	2	22.2	.	.	8	88.9
		Chemotherapy and radiation	78	16	20.5	17	21.8	.	.	46	59.0	4	5.1	5	6.4

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Medulloblastoma/PNET

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		344	56	16.4	85	24.9	.	.	168	49.1	4	1.2	24	7.0
	Age at baseline	<18	123	18	14.6	27	22.0	.	.	70	56.9	1	0.8	20	16.3
		18-19	27	4	15.4	5	19.2	.	.	11	42.3	1	3.8	1	3.8
		20-24	85	14	16.5	21	24.7	.	.	41	48.2	2	2.4	3	3.5
		25-29	69	16	23.5	27	39.7	.	.	38	55.9
		30-34	33	4	12.1	5	15.2	.	.	8	24.2
		35+	7
	Years since diagnosis	5-9	74	16	21.6	24	32.4	.	.	55	74.3	2	2.7	16	21.6
		10-14	127	14	11.1	23	18.3	.	.	55	43.7	.	.	8	6.3
		15-19	107	21	19.8	33	31.1	.	.	47	44.3	2	1.9	.	.
		20+	36	5	13.9	5	13.9	.	.	11	30.6
	Age at diagnosis	<1	10	.	.	1	10.0	.	.	7	70.0	.	.	2	20.0
		1-4	103	17	16.5	19	18.4	.	.	47	45.6	3	2.9	8	7.8
		5-9	137	25	18.4	39	28.7	.	.	67	49.3	.	.	9	6.6
		10-14	70	11	15.9	20	29.0	.	.	36	52.2	1	1.4	3	4.3
		15-20	24	3	12.5	6	25.0	.	.	11	45.8	.	.	2	8.3
	Treatment	Chemotherapy, no radiation	6	.	.	2	33.3	.	.	6	.	.	.	1	16.7
		Chemotherapy and radiation	196	56	28.6	83	42.3	.	.	162	82.7	4	2.0	23	11.7
Males	All cases		203	37	18.2	54	26.6	.	.	106	52.2	3	1.5	18	8.9
	Age at baseline	<18	76	13	17.1	17	22.4	.	.	45	59.2	1	1.3	16	21.1
		18-19	15	3	20.0	3	20.0	.	.	6	40.0	1	6.7	1	6.7
		20-24	50	9	18.0	15	30.0	.	.	27	54.0	1	2.0	1	2.0
		25-29	38	10	26.3	15	39.5	.	.	23	60.5
		30-34	20	2	10.0	4	20.0	.	.	5	25.0
		35+	4
	Years since diagnosis	5-9	48	12	25.0	16	33.3	.	.	35	72.9	2	4.2	12	25.0
		10-14	68	9	13.2	17	25.0	.	.	34	50.0	.	.	6	8.8
		15-19	67	13	19.4	19	28.4	.	.	32	47.8	1	1.5	.	.
		20+	20	3	15.0	2	10.0	.	.	5	25.0
	Age at diagnosis	<1	9	.	.	1	11.1	.	.	6	66.7	.	.	1	11.1
		1-4	59	13	22.0	12	20.3	.	.	30	50.8	2	3.4	7	11.9
		5-9	83	14	16.9	23	27.7	.	.	40	48.2	.	.	7	8.4

		10-14	38	9	23.7	13	34.2	.	.	23	60.5	1	2.6	3	7.9
		15-20	14	1	7.1	5	35.7	.	.	7	50.0
	Treatment	Chemotherapy, no radiation	3	.	.	1	33.3	.	.	3
		Chemotherapy and radiation	124	37	29.8	53	42.7	.	.	103	83.1	3	2.4	18	14.5
Females	All cases		141	19	13.7	31	22.3	.	.	62	44.6	1	0.7	6	4.3
	Age at baseline	<18	47	5	10.6	10	21.3	.	.	25	53.2	.	.	4	8.5
		18-19	12	1	9.1	2	18.2	.	.	5	45.5
		20-24	35	5	14.3	6	17.1	.	.	14	40.0	1	2.9	2	5.7
		25-29	31	6	20.0	12	40.0	.	.	15	50.0
		30-34	13	2	15.4	1	7.7	.	.	3	23.1
		35+	3
	Years since diagnosis	5-9	26	4	15.4	8	30.8	.	.	20	76.9	.	.	4	15.4
		10-14	59	5	8.6	6	10.3	.	.	21	36.2	.	.	2	3.4
		15-19	40	8	20.5	14	35.9	.	.	15	38.5	1	2.6	.	.
		20+	16	2	12.5	3	18.8	.	.	6	37.5
	Age at diagnosis	<1	1	1	.	.	.	1	.
		1-4	44	4	9.1	7	15.9	.	.	17	38.6	1	2.3	1	2.3
		5-9	54	11	20.8	16	30.2	.	.	27	50.9	.	.	2	3.8
		10-14	32	2	6.5	7	22.6	.	.	13	41.9
		15-20	10	2	20.0	1	10.0	.	.	4	40.0	.	.	2	20.0
	Treatment	Chemotherapy, no radiation	3	.	.	1	33.3	.	.	3	.	.	.	1	33.3
		Chemotherapy and radiation	72	19	26.4	30	41.7	.	.	59	81.9	1	1.4	5	6.9

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Hodgkin

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1675	54	3.2	843	50.5	491	29.4	907	54.3	4	0.2	56	3.4
	Age at baseline	<18	44	2	4.5	23	52.3	23	52.3	28	63.6	.	.	4	9.1
		18-19	38	1	2.6	21	55.3	17	44.7	23	60.5	.	.	3	7.9
		20-24	226	14	6.2	135	60.0	101	44.9	144	64.0	1	0.4	9	4.0
		25-29	422	19	4.5	228	54.0	145	34.4	225	53.3	2	0.5	20	4.7
		30-34	474	14	3.0	238	50.3	130	27.5	262	55.4	.	.	17	3.6
		35+	471	4	0.9	198	42.3	75	16.0	225	48.1	1	0.2	3	0.6
	Years since diagnosis	5-9	193	18	9.3	114	59.1	115	59.6	114	59.1	2	1.0	26	13.5
		10-14	523	27	5.2	261	50.1	210	40.3	276	53.0	1	0.2	19	3.6
		15-19	492	5	1.0	258	52.5	103	21.0	281	57.2	1	0.2	9	1.8
		20+	467	4	0.9	210	45.2	63	13.5	236	50.8	.	.	2	0.4
	Age at diagnosis	1-4	47	.	.	20	42.6	8	17.0	26	55.3
		5-9	211	5	2.4	116	55.0	54	25.6	127	60.2	.	.	8	3.8
		10-14	577	18	3.1	325	56.4	170	29.5	354	61.5	2	0.3	12	2.1
		15-20	840	31	3.7	382	45.7	259	31.0	400	47.8	2	0.2	36	4.3
	Treatment	Chemotherapy, no radiation	98	3	3.1	88	89.8	58	59.2	72	73.5	.	.	4	4.1
		Chemotherapy and radiation	1024	51	5.0	755	73.7	433	42.3	835	81.5	4	0.4	52	5.1
Males	All cases		891	37	4.2	465	52.3	278	31.3	486	54.7	1	0.1	35	3.9
	Age at baseline	<18	34	.	.	16	47.1	19	55.9	21	61.8	.	.	3	8.8
		18-19	31	1	3.2	17	54.8	14	45.2	18	58.1	.	.	3	9.7
		20-24	144	8	5.6	85	59.4	65	45.5	87	60.8	.	.	5	3.5
		25-29	244	14	5.7	138	56.6	78	32.0	133	54.5	1	0.4	14	5.7
		30-34	237	12	5.1	118	49.8	72	30.4	125	52.7	.	.	9	3.8
		35+	201	2	1.0	91	45.5	30	15.0	102	51.0	.	.	1	0.5
	Years since diagnosis	5-9	115	10	8.7	70	60.9	69	60.0	69	60.0	.	.	18	15.7
		10-14	281	20	7.1	145	51.8	122	43.6	147	52.5	1	0.4	9	3.2
		15-19	270	4	1.5	144	53.3	58	21.5	155	57.4	.	.	7	2.6
		20+	225	3	1.3	106	47.3	29	12.9	115	51.3	.	.	1	0.4
	Age at diagnosis	1-4	36	.	.	15	41.7	8	22.2	20	55.6
		5-9	156	2	1.3	85	54.5	44	28.2	92	59.0	.	.	7	4.5
		10-14	297	11	3.7	170	57.4	92	31.1	180	60.8	1	0.3	8	2.7
		15-20	402	24	6.0	195	48.6	134	33.4	194	48.4	.	.	20	5.0
	Treatment	Chemotherapy, no radiation	52	2	3.8	47	90.4	31	59.6	36	69.2	.	.	2	3.8

		Chemotherapy and radiation	552	35	6.3	418	75.7	247	44.7	450	81.5	1	0.2	33	6.0
Females	All cases		784	17	2.2	378	48.4	213	27.3	421	53.9	3	0.4	21	2.7
	Age at baseline	<18	10	2	20.0	7	70.0	4	40.0	7	70.0	.	.	1	10.0
		18-19	7	.	.	4	57.1	3	42.9	5	71.4
		20-24	82	6	7.3	50	61.0	36	43.9	57	69.5	1	1.2	4	4.9
		25-29	178	5	2.8	90	50.6	67	37.6	92	51.7	1	0.6	6	3.4
		30-34	237	2	0.8	120	50.8	58	24.6	137	58.1	.	.	8	3.4
		35+	270	2	0.7	107	39.9	45	16.8	123	45.9	1	0.4	2	0.7
	Years since diagnosis	5-9	78	8	10.3	44	56.4	46	59.0	45	57.7	2	2.6	8	10.3
		10-14	242	7	2.9	116	48.1	88	36.5	129	53.5	.	.	10	4.1
		15-19	222	1	0.5	114	51.6	45	20.4	126	57.0	1	0.5	2	0.9
		20+	242	1	0.4	104	43.2	34	14.1	121	50.2	.	.	1	0.4
	Age at diagnosis	1-4	11	.	.	5	45.5	.	.	6	54.5
		5-9	55	3	5.5	31	56.4	10	18.2	35	63.6	.	.	1	1.8
		10-14	280	7	2.5	155	55.4	78	27.9	174	62.1	1	0.4	4	1.4
		15-20	438	7	1.6	187	43.0	125	28.7	206	47.4	2	0.5	16	3.7
	Treatment	Chemotherapy, no radiation	46	1	2.2	41	89.1	27	58.7	36	78.3	.	.	2	4.3
		Chemotherapy and radiation	472	16	3.4	337	71.4	186	39.4	385	81.6	3	0.6	19	4.0

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: NHL

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		925	73	7.9	805	87.1	23	2.5	837	90.6	47	5.1	42	4.5
	Age at baseline	<18	144	6	4.2	132	91.7	6	4.2	134	93.1	12	8.3	15	10.4
		18-19	76	7	9.2	68	89.5	.	.	71	93.4	6	7.9	4	5.3
		20-24	198	19	9.6	182	91.9	5	2.5	190	96.0	9	4.5	7	3.5
		25-29	227	19	8.4	204	89.9	7	3.1	211	93.0	10	4.4	7	3.1
		30-34	182	17	9.3	152	83.5	3	1.6	163	89.6	10	5.5	8	4.4
		35+	98	5	5.2	67	69.1	2	2.1	68	70.1	.	.	1	1.0
	Years since diagnosis	5-9	110	13	11.8	99	90.0	1	0.9	105	95.5	12	10.9	15	13.6
		10-14	358	34	9.5	318	88.8	9	2.5	331	92.5	21	5.9	25	7.0
		15-19	278	21	7.6	252	90.6	8	2.9	263	94.6	12	4.3	2	0.7
		20+	179	5	2.8	136	76.4	5	2.8	138	77.5	2	1.1	.	.
	Age at diagnosis	<1	8	.	.	6	75.0	1	12.5	4	50.0
		1-4	150	7	4.7	134	89.3	8	5.3	138	92.0	6	4.0	5	3.3
		5-9	280	19	6.8	253	90.4	4	1.4	268	95.7	16	5.7	14	5.0
		10-14	282	23	8.2	260	92.2	6	2.1	263	93.3	15	5.3	10	3.5
		15-20	205	24	11.8	152	74.5	4	2.0	164	80.4	10	4.9	13	6.4
	Treatment	Chemotherapy, no radiation	276	19	6.9	253	91.7	8	2.9	264	95.7	19	6.9	12	4.3
		Chemotherapy and radiation	598	54	9.0	551	92.1	15	2.5	572	95.7	28	4.7	30	5.0
Males	All cases		645	46	7.1	557	86.5	12	1.9	579	89.9	35	5.4	28	4.3
	Age at baseline	<18	101	4	4.0	94	93.1	4	4.0	96	95.0	11	10.9	12	11.9
		18-19	61	7	11.5	55	90.2	.	.	56	91.8	3	4.9	3	4.9
		20-24	136	14	10.3	122	89.7	1	0.7	130	95.6	8	5.9	4	2.9
		25-29	162	10	6.2	149	92.0	5	3.1	151	93.2	6	3.7	4	2.5
		30-34	122	10	8.2	97	79.5	1	0.8	105	86.1	7	5.7	5	4.1
		35+	63	1	1.6	40	64.5	1	1.6	41	66.1
	Years since diagnosis	5-9	84	11	13.1	76	90.5	1	1.2	80	95.2	11	13.1	12	14.3
		10-14	254	21	8.3	227	89.4	6	2.4	234	92.1	16	6.3	15	5.9
		15-19	177	12	6.8	159	89.8	1	0.6	168	94.9	6	3.4	1	0.6
		20+	130	2	1.6	95	73.6	4	3.1	97	75.2	2	1.6	.	.
	Age at diagnosis	<1	3	.	.	1	33.3	.	.	1	33.3
		1-4	103	6	5.8	93	90.3	4	3.9	96	93.2	5	4.9	4	3.9
		5-9	204	12	5.9	183	89.7	4	2.0	193	94.6	11	5.4	10	4.9
		10-14	202	16	7.9	187	92.6	2	1.0	188	93.1	12	5.9	6	3.0

		15-20	133	12	9.1	93	70.5	2	1.5	101	76.5	7	5.3	8	6.1
	Treatment	Chemotherapy, no radiation	205	12	5.9	185	90.2	6	2.9	193	94.1	17	8.3	9	4.4
		Chemotherapy and radiation	401	34	8.5	371	92.5	6	1.5	385	96.0	18	4.5	19	4.7
Females	All cases		280	27	9.6	248	88.6	11	3.9	258	92.1	12	4.3	14	5.0
	Age at baseline	<18	43	2	4.7	38	88.4	2	4.7	38	88.4	1	2.3	3	7.0
		18-19	15	.	.	13	86.7	.	.	15	.	3	20.0	1	6.7
		20-24	62	5	8.1	60	96.8	4	6.5	60	96.8	1	1.6	3	4.8
		25-29	65	9	13.8	55	84.6	2	3.1	60	92.3	4	6.2	3	4.6
		30-34	60	7	11.7	55	91.7	2	3.3	58	96.7	3	5.0	3	5.0
		35+	35	4	11.4	27	77.1	1	2.9	27	77.1	.	.	1	2.9
	Years since diagnosis	5-9	26	2	7.7	23	88.5	.	.	25	96.2	1	3.8	3	11.5
		10-14	104	13	12.5	91	87.5	3	2.9	97	93.3	5	4.8	10	9.6
		15-19	101	9	8.9	93	92.1	7	6.9	95	94.1	6	5.9	1	1.0
		20+	49	3	6.1	41	83.7	1	2.0	41	83.7
	Age at diagnosis	<1	5	.	.	5	.	1	20.0	3	60.0
		1-4	47	1	2.1	41	87.2	4	8.5	42	89.4	1	2.1	1	2.1
		5-9	76	7	9.2	70	92.1	.	.	75	98.7	5	6.6	4	5.3
		10-14	80	7	8.8	73	91.3	4	5.0	75	93.8	3	3.8	4	5.0
		15-20	72	12	16.7	59	81.9	2	2.8	63	87.5	3	4.2	5	6.9
	Treatment	Chemotherapy, no radiation	71	7	9.9	68	95.8	2	2.8	71	.	2	2.8	3	4.2
		Chemotherapy and radiation	197	20	10.2	180	91.4	9	4.6	187	94.9	10	5.1	11	5.6

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Wilms

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1088	7	0.6	8	0.7	9	0.8	995	91.5	5	0.5	33	3.0
	Age at baseline	<18	523	6	1.1	4	0.8	8	1.5	497	95.0	4	0.8	26	5.0
		18-19	131	1	0.8	125	95.4	1	0.8	3	2.3
		20-24	249	1	0.4	2	0.8	.	.	232	93.2	.	.	2	0.8
		25-29	149	.	.	2	1.3	.	.	117	78.5	.	.	2	1.3
		30-34	28	19	67.9
		35+	8	5	62.5
	Years since diagnosis	5-9	145	3	2.1	3	2.1	2	1.4	139	95.9	1	0.7	20	13.8
		10-14	436	4	0.9	2	0.5	7	1.6	415	95.2	4	0.9	12	2.8
		15-19	279	.	.	1	0.4	.	.	268	96.1	.	.	1	0.4
		20+	228	.	.	2	0.9	.	.	173	75.9
	Age at diagnosis	<1	162	1	0.6	1	0.6	2	1.2	134	82.7	1	0.6	2	1.2
		1-4	659	2	0.3	3	0.5	5	0.8	616	93.5	2	0.3	16	2.4
		5-9	225	2	0.9	2	0.9	2	0.9	208	92.4	2	0.9	9	4.0
		10-14	30	1	3.3	1	3.3	.	.	27	90.0	.	.	5	16.7
		15-20	12	1	8.3	1	8.3	.	.	10	83.3	.	.	1	8.3
	Treatment	Chemotherapy, no radiation	369	1	0.3	1	0.3	4	1.1	343	93.0	1	0.3	2	0.5
		Chemotherapy and radiation	701	6	0.9	7	1.0	5	0.7	652	93.0	4	0.6	31	4.4
Males	All cases		502	4	0.8	2	0.4	6	1.2	453	90.2	1	0.2	17	3.4
	Age at baseline	<18	253	4	1.6	.	.	6	2.4	239	94.5	.	.	13	5.1
		18-19	58	54	93.1	1	1.7	.	.
		20-24	105	.	.	1	1.0	.	.	100	95.2	.	.	2	1.9
		25-29	75	.	.	1	1.3	.	.	52	69.3	.	.	2	2.7
		30-34	9	6	66.7
		35+	2	2
	Years since diagnosis	5-9	62	2	3.2	.	.	2	3.2	58	93.5	.	.	8	12.9
		10-14	207	2	1.0	.	.	4	1.9	198	95.7	1	0.5	8	3.9
		15-19	122	.	.	1	0.8	.	.	117	95.9	.	.	1	0.8
		20+	111	.	.	1	0.9	.	.	80	72.1
	Age at diagnosis	<1	87	1	1.1	.	.	1	1.1	71	81.6
		1-4	309	1	0.3	1	0.3	4	1.3	284	91.9	.	.	9	2.9
		5-9	90	1	1.1	.	.	1	1.1	83	92.2	1	1.1	3	3.3
		10-14	12	1	8.3	1	8.3	.	.	11	91.7	.	.	4	33.3

		15-20	4	4	.	.	.	1	25.0
	Treatment	Chemotherapy, no radiation	179	2	1.1	166	92.7	.	.	2	1.1
		Chemotherapy and radiation	315	4	1.3	2	0.6	4	1.3	287	91.1	1	0.3	15	4.8
Females	All cases		586	3	0.5	6	1.0	3	0.5	542	92.5	4	0.7	16	2.7
	Age at baseline	<18	270	2	0.7	4	1.5	2	0.7	258	95.6	4	1.5	13	4.8
		18-19	73	1	1.4	71	97.3	.	.	3	4.1
		20-24	144	1	0.7	1	0.7	.	.	132	91.7
		25-29	74	.	.	1	1.4	.	.	65	87.8
		30-34	19	13	68.4
		35+	6	3	50.0
	Years since diagnosis	5-9	83	1	1.2	3	3.6	.	.	81	97.6	1	1.2	12	14.5
		10-14	229	2	0.9	2	0.9	3	1.3	217	94.8	3	1.3	4	1.7
		15-19	157	151	96.2
		20+	117	.	.	1	0.9	.	.	93	79.5
	Age at diagnosis	<1	75	.	.	1	1.3	1	1.3	63	84.0	1	1.3	2	2.7
		1-4	350	1	0.3	2	0.6	1	0.3	332	94.9	2	0.6	7	2.0
		5-9	135	1	0.7	2	1.5	1	0.7	125	92.6	1	0.7	6	4.4
		10-14	18	16	88.9	.	.	1	5.6
		15-20	8	1	12.5	1	12.5	.	.	6	75.0
	Treatment	Chemotherapy, no radiation	190	1	0.5	1	0.5	2	1.1	177	93.2	1	0.5	.	.
		Chemotherapy and radiation	386	2	0.5	5	1.3	1	0.3	365	94.6	3	0.8	16	4.1

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Neuroblastoma

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		833	19	2.3	14	1.7	7	0.8	306	36.8	87	10.5	22	2.6
	Age at baseline	<18	480	15	3.1	8	1.7	7	1.5	159	33.2	71	14.8	19	4.0
		18-19	96	.	.	1	1.0	.	.	37	38.5	9	9.4	2	2.1
		20-24	177	1	0.6	3	1.7	.	.	76	42.9	6	3.4	.	.
		25-29	59	2	3.4	2	3.4	.	.	25	42.4	1	1.7	1	1.7
		30-34	19	1	5.6	9	50.0
		35+	2
	Years since diagnosis	5-9	98	5	5.1	4	4.1	3	3.1	42	42.9	28	28.6	14	14.3
		10-14	296	12	4.1	5	1.7	4	1.4	92	31.1	38	12.8	6	2.0
		15-19	249	1	0.4	96	38.7	20	8.1	1	0.4
		20+	190	1	0.5	5	2.6	.	.	76	40.2	1	0.5	1	0.5
	Age at diagnosis	<1	457	6	1.3	5	1.1	5	1.1	140	30.7	26	5.7	4	0.9
		1-4	301	8	2.7	8	2.7	1	0.3	130	43.2	47	15.6	12	4.0
		5-9	57	1	1.8	1	1.8	1	1.8	28	50.0	12	21.4	6	10.7
		10-14	12	3	25.0	6	50.0	1	8.3	.	.
		15-20	6	1	16.7	2	33.3	1	16.7	.	.
	Treatment	Chemotherapy, no radiation	220	6	2.7	3	1.4	5	2.3	102	46.4	37	16.8	6	2.7
		Chemotherapy and radiation	273	13	4.8	11	4.0	2	0.7	204	74.7	50	18.3	16	5.9
Males	All cases		388	6	1.6	7	1.8	4	1.0	135	34.9	40	10.3	6	1.6
	Age at baseline	<18	223	5	2.3	4	1.8	4	1.8	64	28.8	32	14.4	5	2.3
		18-19	43	.	.	1	2.3	.	.	21	48.8	6	14.0	1	2.3
		20-24	84	.	.	1	1.2	.	.	31	36.9	2	2.4	.	.
		25-29	26	.	.	1	3.8	.	.	12	46.2
		30-34	11	1	9.1	7	63.6
		35+	1
	Years since diagnosis	5-9	45	2	4.4	3	6.7	2	4.4	16	35.6	13	28.9	5	11.1
		10-14	140	3	2.1	2	1.4	2	1.4	36	25.7	16	11.4	1	0.7
		15-19	111	1	0.9	47	42.7	11	10.0	.	.
		20+	92	.	.	2	2.2	.	.	36	39.1
	Age at diagnosis	<1	232	1	0.4	1	0.4	3	1.3	62	26.8	14	6.1	1	0.4
		1-4	123	3	2.4	5	4.1	.	.	54	43.9	21	17.1	4	3.3
		5-9	24	.	.	1	4.2	1	4.2	15	62.5	3	12.5	1	4.2

		10-14	6	1	16.7	2	33.3	1	16.7	.	.
		15-20	3	1	33.3	2	66.7	1	33.3	.	.
	Treatment	Chemotherapy, no radiation	101	2	2.0	1	1.0	2	2.0	43	42.6	15	14.9	2	2.0
		Chemotherapy and radiation	126	4	3.2	6	4.8	2	1.6	92	73.0	25	19.8	4	3.2
Females	All cases		445	13	2.9	7	1.6	3	0.7	171	38.5	47	10.6	16	3.6
	Age at baseline	<18	257	10	3.9	4	1.6	3	1.2	95	37.0	39	15.2	14	5.4
		18-19	53	16	30.2	3	5.7	1	1.9
		20-24	93	1	1.1	2	2.2	.	.	45	48.4	4	4.3	.	.
		25-29	33	2	6.1	1	3.0	.	.	13	39.4	1	3.0	1	3.0
		30-34	8	2	28.6
		35+	1
	Years since diagnosis	5-9	53	3	5.7	1	1.9	1	1.9	26	49.1	15	28.3	9	17.0
		10-14	156	9	5.8	3	1.9	2	1.3	56	35.9	22	14.1	5	3.2
		15-19	138	49	35.5	9	6.5	1	0.7
		20+	98	1	1.0	3	3.1	.	.	40	41.2	1	1.0	1	1.0
	Age at diagnosis	<1	225	5	2.2	4	1.8	2	0.9	78	34.7	12	5.3	3	1.3
		1-4	178	5	2.8	3	1.7	1	0.6	76	42.7	26	14.6	8	4.5
		5-9	33	1	3.1	13	40.6	9	28.1	5	15.6
		10-14	6	2	33.3	4	66.7
		15-20	3
	Treatment	Chemotherapy, no radiation	119	4	3.4	2	1.7	3	2.5	59	49.6	22	18.5	4	3.4
		Chemotherapy and radiation	147	9	6.1	5	3.4	.	.	112	76.2	25	17.0	12	8.2

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: STS

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1092	45	4.1	21	1.9	6	0.6	802	73.6	8	0.7	78	7.2
	Age at baseline	<18	229	10	4.4	4	1.8	2	0.9	198	86.8	4	1.8	42	18.4
		18-19	83	5	6.0	1	1.2	.	.	75	90.4	2	2.4	7	8.4
		20-24	224	12	5.4	4	1.8	2	0.9	177	79.0	2	0.9	20	8.9
		25-29	230	9	3.9	4	1.7	1	0.4	166	72.2	.	.	6	2.6
		30-34	191	7	3.7	7	3.7	.	.	121	63.7	.	.	3	1.6
		35+	135	2	1.5	1	0.7	1	0.7	65	48.5
	Years since diagnosis	5-9	152	10	6.6	7	4.6	2	1.3	115	76.2	5	3.3	43	28.5
		10-14	337	26	7.7	4	1.2	3	0.9	242	71.8	3	0.9	32	9.5
		15-19	323	7	2.2	4	1.2	.	.	254	78.6	.	.	3	0.9
		20+	280	2	0.7	6	2.2	1	0.4	191	68.7
	Age at diagnosis	<1	80	2	2.5	.	.	1	1.3	58	72.5	1	1.3	3	3.8
		1-4	305	10	3.3	4	1.3	1	0.3	276	90.5	3	1.0	33	10.8
		5-9	223	8	3.6	7	3.1	.	.	189	84.8	1	0.4	19	8.5
		10-14	231	12	5.2	6	2.6	2	0.9	157	68.6	2	0.9	9	3.9
		15-20	253	13	5.2	4	1.6	2	0.8	122	48.4	1	0.4	14	5.6
	Treatment	Chemotherapy, no radiation	230	13	5.7	2	0.9	.	.	206	89.6	.	.	8	3.5
		Chemotherapy and radiation	631	32	5.1	19	3.0	6	1.0	595	94.3	8	1.3	70	11.1
Males	All cases		563	29	5.2	11	2.0	4	0.7	432	76.9	5	0.9	53	9.4
	Age at baseline	<18	127	6	4.7	2	1.6	1	0.8	113	89.0	2	1.6	31	24.4
		18-19	42	4	9.5	1	2.4	.	.	39	92.9	2	4.8	5	11.9
		20-24	124	9	7.3	1	0.8	1	0.8	97	78.2	1	0.8	11	8.9
		25-29	112	6	5.4	3	2.7	1	0.9	86	76.8	.	.	4	3.6
		30-34	96	4	4.2	3	3.2	.	.	64	67.4	.	.	2	2.1
		35+	62	.	.	1	1.6	1	1.6	33	53.2
	Years since diagnosis	5-9	80	3	3.8	3	3.8	.	.	65	81.3	3	3.8	27	33.8
		10-14	176	21	11.9	3	1.7	3	1.7	130	73.9	2	1.1	24	13.6
		15-19	157	3	1.9	2	1.3	.	.	131	83.4	.	.	2	1.3
		20+	150	2	1.3	3	2.0	1	0.7	106	71.1
	Age at diagnosis	<1	34	1	2.9	27	79.4	.	.	2	5.9
		1-4	183	7	3.8	2	1.1	1	0.5	164	89.6	2	1.1	25	13.7
		5-9	120	7	5.8	4	3.3	.	.	101	84.2	1	0.8	14	11.7
		10-14	114	9	8.0	2	1.8	2	1.8	80	70.8	2	1.8	5	4.4

		15-20	112	5	4.5	3	2.7	1	0.9	60	53.6	.	.	7	6.3
	Treatment	Chemotherapy, no radiation	127	7	5.5	1	0.8	.	.	118	92.9	.	.	7	5.5
		Chemotherapy and radiation	331	22	6.6	10	3.0	4	1.2	314	94.9	5	1.5	46	13.9
Females	All cases		529	16	3.0	10	1.9	2	0.4	370	70.2	3	0.6	25	4.7
	Age at baseline	<18	102	4	4.0	2	2.0	1	1.0	85	84.2	2	2.0	11	10.9
		18-19	41	1	2.4	36	87.8	.	.	2	4.9
		20-24	100	3	3.0	3	3.0	1	1.0	80	80.0	1	1.0	9	9.0
		25-29	118	3	2.5	1	0.8	.	.	80	67.8	.	.	2	1.7
		30-34	95	3	3.2	4	4.2	.	.	57	60.0	.	.	1	1.1
		35+	73	2	2.8	32	44.4
	Years since diagnosis	5-9	72	7	9.9	4	5.6	2	2.8	50	70.4	2	2.8	16	22.5
		10-14	161	5	3.1	1	0.6	.	.	112	69.6	1	0.6	8	5.0
		15-19	166	4	2.4	2	1.2	.	.	123	74.1	.	.	1	0.6
		20+	130	.	.	3	2.3	.	.	85	65.9
	Age at diagnosis	<1	46	1	2.2	.	.	1	2.2	31	67.4	1	2.2	1	2.2
		1-4	122	3	2.5	2	1.6	.	.	112	91.8	1	0.8	8	6.6
		5-9	103	1	1.0	3	2.9	.	.	88	85.4	.	.	5	4.9
		10-14	117	3	2.6	4	3.4	.	.	77	66.4	.	.	4	3.4
		15-20	141	8	5.7	1	0.7	1	0.7	62	44.3	1	0.7	7	5.0
	Treatment	Chemotherapy, no radiation	103	6	5.8	1	1.0	.	.	88	85.4	.	.	1	1.0
		Chemotherapy and radiation	300	10	3.3	9	3.0	2	0.7	281	93.7	3	1.0	24	8.0

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: All bone

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1044	97	9.3	17	1.6	6	0.6	682	65.3	3	0.3	61	5.8
	Age at baseline	<18	47	1	2.1	1	2.1	.	.	38	80.9	.	.	12	25.5
		18-19	43	6	14.0	2	4.7	1	2.3	34	79.1	1	2.3	6	14.0
		20-24	211	33	15.6	2	0.9	3	1.4	155	73.5	1	0.5	35	16.6
		25-29	266	25	9.4	4	1.5	.	.	164	61.7	.	.	6	2.3
		30-34	285	29	10.2	7	2.5	1	0.4	177	62.1	1	0.4	1	0.4
		35+	192	3	1.6	1	0.5	1	0.5	114	59.4	.	.	1	0.5
	Years since diagnosis	5-9	152	20	13.2	6	3.9	3	2.0	124	81.6	1	0.7	42	27.6
		10-14	357	59	16.5	5	1.4	1	0.3	203	56.9	1	0.3	16	4.5
		15-19	331	17	5.1	5	1.5	1	0.3	222	67.1	1	0.3	3	0.9
		20+	204	1	0.5	1	0.5	1	0.5	133	65.2
	Age at diagnosis	<1	1	1
		1-4	35	3	8.6	28	80.0	.	.	3	8.6
		5-9	176	9	5.1	3	1.7	.	.	131	74.4	.	.	14	8.0
		10-14	395	37	9.4	7	1.8	3	0.8	272	68.9	3	0.8	28	7.1
		15-20	437	48	11.0	7	1.6	3	0.7	250	57.2	.	.	16	3.7
	Treatment	Chemotherapy, no radiation	567	70	12.3	7	1.2	1	0.2	348	61.4	.	.	18	3.2
		Chemotherapy and radiation	370	27	7.3	10	2.7	5	1.4	333	90.0	3	0.8	43	11.6
Males	All cases		528	52	9.8	10	1.9	4	0.8	352	66.7	3	0.6	32	6.1
	Age at baseline	<18	24	20	83.3	.	.	7	29.2
		18-19	24	3	12.5	2	8.3	1	4.2	19	79.2	1	4.2	3	12.5
		20-24	99	14	14.1	.	.	2	2.0	77	77.8	1	1.0	17	17.2
		25-29	137	12	8.8	3	2.2	.	.	83	60.6	.	.	4	2.9
		30-34	143	21	14.7	4	2.8	.	.	91	63.6	1	0.7	1	0.7
		35+	101	2	2.0	1	1.0	1	1.0	62	61.4
	Years since diagnosis	5-9	77	10	13.0	3	3.9	3	3.9	67	87.0	1	1.3	24	31.2
		10-14	188	32	17.0	5	2.7	.	.	106	56.4	1	0.5	8	4.3
		15-19	167	9	5.4	2	1.2	.	.	115	68.9	1	0.6	.	.
		20+	96	1	1.0	.	.	1	1.0	64	66.7
	Age at diagnosis	<1	1	1
		1-4	16	2	12.5	14	87.5
		5-9	96	4	4.2	1	1.0	.	.	71	74.0	.	.	8	8.3
		10-14	178	12	6.7	4	2.2	1	0.6	130	73.0	3	1.7	15	8.4

		15-20	237	34	14.3	5	2.1	3	1.3	136	57.4	.	.	9	3.8
	Treatment	Chemotherapy, no radiation	292	35	12.0	4	1.4	.	.	180	61.6	.	.	10	3.4
		Chemotherapy and radiation	190	17	8.9	6	3.2	4	2.1	171	90.0	3	1.6	22	11.6
Females	All cases		516	45	8.7	7	1.4	2	0.4	330	64.0	.	.	29	5.6
	Age at baseline	<18	23	1	4.3	1	4.3	.	.	18	78.3	.	.	5	21.7
		18-19	19	3	15.8	15	78.9	.	.	3	15.8
		20-24	112	19	17.0	2	1.8	1	0.9	78	69.6	.	.	18	16.1
		25-29	129	13	10.1	1	0.8	.	.	81	62.8	.	.	2	1.6
		30-34	142	8	5.6	3	2.1	1	0.7	86	60.6
		35+	91	1	1.1	52	57.1	.	.	1	1.1
	Years since diagnosis	5-9	75	10	13.3	3	4.0	.	.	57	76.0	.	.	18	24.0
		10-14	169	27	16.0	.	.	1	0.6	97	57.4	.	.	8	4.7
		15-19	164	8	4.9	3	1.8	1	0.6	107	65.2	.	.	3	1.8
		20+	108	.	.	1	0.9	.	.	69	63.9
	Age at diagnosis	1-4	19	1	5.3	14	73.7	.	.	3	15.8
		5-9	80	5	6.3	2	2.5	.	.	60	75.0	.	.	6	7.5
		10-14	217	25	11.5	3	1.4	2	0.9	142	65.4	.	.	13	6.0
		15-20	200	14	7.0	2	1.0	.	.	114	57.0	.	.	7	3.5
	Treatment	Chemotherapy, no radiation	275	35	12.7	3	1.1	1	0.4	168	61.1	.	.	8	2.9
		Chemotherapy and radiation	180	10	5.6	4	2.2	1	0.6	162	90.0	.	.	21	11.7

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Ewings

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		360	28	7.8	6	1.7	3	0.8	347	96.4	3	0.8	42	11.7
	Age at baseline	<18	31	.	.	1	3.2	.	.	28	90.3	.	.	11	35.5
		18-19	23	4	17.4	2	8.7	1	4.3	23	.	1	4.3	5	21.7
		20-24	94	15	16.0	1	1.1	1	1.1	92	97.9	1	1.1	21	22.3
		25-29	91	3	3.3	91	.	.	.	4	4.4
		30-34	81	6	7.4	1	1.2	1	1.2	77	95.1	1	1.2	.	.
		35+	40	.	.	1	2.5	.	.	36	90.0	.	.	1	2.5
	Years since diagnosis	5-9	67	6	9.0	4	6.0	2	3.0	64	95.5	1	1.5	26	38.8
		10-14	126	18	14.3	124	98.4	1	0.8	13	10.3
		15-19	107	4	3.7	1	0.9	1	0.9	104	97.2	1	0.9	3	2.8
		20+	60	.	.	1	1.7	.	.	55	91.7
	Age at diagnosis	<1	1	1
		1-4	23	2	8.7	22	95.7	.	.	2	8.7
		5-9	95	5	5.3	3	3.2	.	.	91	95.8	.	.	14	14.7
		10-14	132	10	7.6	2	1.5	2	1.5	126	95.5	3	2.3	16	12.1
		15-20	109	11	10.1	1	0.9	1	0.9	107	98.2	.	.	10	9.2
	Treatment	Chemotherapy, no radiation	70	6	8.6	1	1.4	1	1.4	69	98.6	.	.	6	8.6
		Chemotherapy and radiation	288	22	7.6	5	1.7	2	0.7	278	96.5	3	1.0	36	12.5
Males	All cases		186	17	9.1	3	1.6	2	1.1	180	96.8	3	1.6	24	12.9
	Age at baseline	<18	15	14	93.3	.	.	7	46.7
		18-19	14	2	14.3	2	14.3	1	7.1	14	.	1	7.1	3	21.4
		20-24	50	9	18.0	.	.	1	2.0	48	96.0	1	2.0	12	24.0
		25-29	44	1	2.3	44	.	.	.	2	4.5
		30-34	42	5	11.9	41	97.6	1	2.4	.	.
		35+	21	.	.	1	4.8	.	.	19	90.5
	Years since diagnosis	5-9	38	4	10.5	2	5.3	2	5.3	36	94.7	1	2.6	19	50.0
		10-14	62	9	14.5	61	98.4	1	1.6	5	8.1
		15-19	56	4	7.1	1	1.8	.	.	55	98.2	1	1.8	.	.
		20+	30	28	93.3
	Age at diagnosis	<1	1	1
		1-4	12	2	16.7	12
		5-9	50	3	6.0	1	2.0	.	.	48	96.0	.	.	8	16.0
		10-14	68	4	5.9	1	1.5	1	1.5	66	97.1	3	4.4	10	14.7

		15-20	55	8	14.5	1	1.8	1	1.8	53	96.4	.	.	6	10.9
	Treatment	Chemotherapy, no radiation	39	4	10.3	1	2.6	.	.	39	.	.	.	4	10.3
		Chemotherapy and radiation	146	13	8.9	2	1.4	2	1.4	141	96.6	3	2.1	20	13.7
Females	All cases		174	11	6.3	3	1.7	1	0.6	167	96.0	.	.	18	10.3
	Age at baseline	<18	16	.	.	1	6.3	.	.	14	87.5	.	.	4	25.0
		18-19	9	2	22.2	9	.	.	.	2	22.2
		20-24	44	6	13.6	1	2.3	.	.	44	.	.	.	9	20.5
		25-29	47	2	4.3	47	.	.	.	2	4.3
		30-34	39	1	2.6	1	2.6	1	2.6	36	92.3
		35+	19	17	89.5	.	.	1	5.3
	Years since diagnosis	5-9	29	2	6.9	2	6.9	.	.	28	96.6	.	.	7	24.1
		10-14	64	9	14.1	63	98.4	.	.	8	12.5
		15-19	51	1	2.0	49	96.1	.	.	3	5.9
		20+	30	.	.	1	3.3	.	.	27	90.0
	Age at diagnosis	1-4	11	10	90.9	.	.	2	18.2
		5-9	45	2	4.4	2	4.4	.	.	43	95.6	.	.	6	13.3
		10-14	64	6	9.4	1	1.6	1	1.6	60	93.8	.	.	6	9.4
		15-20	54	3	5.6	54	.	.	.	4	7.4
	Treatment	Chemotherapy, no radiation	31	2	6.5	.	.	1	3.2	30	96.8	.	.	2	6.5
		Chemotherapy and radiation	142	9	6.3	3	2.1	.	.	137	96.5	.	.	16	11.3

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.

Chemotherapy agents - Steroids, plant alkyloids and epipodophyllotoxins: Osteosarcoma

[Click here to see the Medical Records Abstraction Form for Survivors](#)

			Dexamethasone		Prednisone		Vinblastine		Vincristine		VM-26 Teniposide		VM-16 (Etoposide)		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		638	69	10.8	10	1.6	3	0.5	324	50.8	.	.	16	2.5
	Age at baseline	<18	14	1	7.1	9	64.3
		18-19	18	2	11.1	11	61.1	.	.	1	5.6
		20-24	110	18	16.4	1	0.9	2	1.8	60	54.5	.	.	13	11.8
		25-29	166	22	13.3	3	1.8	.	.	68	41.0	.	.	1	0.6
		30-34	192	23	12.0	6	3.1	.	.	99	51.6	.	.	1	0.5
		35+	138	3	2.2	.	.	1	0.7	77	55.8
	Years since diagnosis	5-9	79	14	17.7	1	1.3	1	1.3	56	70.9	.	.	13	16.5
		10-14	215	41	19.1	5	2.3	1	0.5	76	35.3	.	.	3	1.4
		15-19	213	13	6.1	4	1.9	.	.	116	54.5
		20+	131	1	0.8	.	.	1	0.8	76	58.0
	Age at diagnosis	1-4	10	1	10.0	5	50.0
		5-9	72	4	5.6	38	52.8
		10-14	254	27	10.6	5	2.0	1	0.4	142	55.9	.	.	11	4.3
		15-20	302	37	12.3	5	1.7	2	0.7	139	46.0	.	.	5	1.7
	Treatment	Chemotherapy, no radiation	492	64	13.0	6	1.2	.	.	275	55.9	.	.	12	2.4
		Chemotherapy and radiation	74	5	6.8	4	5.4	3	4.1	48	64.9	.	.	4	5.4
Males	All cases		320	35	10.9	6	1.9	2	0.6	168	52.5	.	.	7	2.2
	Age at baseline	<18	9	6	66.7
		18-19	8	1	12.5	5	62.5
		20-24	46	5	10.9	.	.	1	2.2	28	60.9	.	.	5	10.9
		25-29	88	11	12.5	2	2.3	.	.	37	42.0	.	.	1	1.1
		30-34	94	16	17.0	4	4.3	.	.	49	52.1	.	.	1	1.1
		35+	75	2	2.7	.	.	1	1.3	43	57.3
	Years since diagnosis	5-9	37	6	16.2	.	.	1	2.7	30	81.1	.	.	4	10.8
		10-14	119	23	19.3	5	4.2	.	.	44	37.0	.	.	3	2.5
		15-19	104	5	4.8	1	1.0	.	.	59	56.7
		20+	60	1	1.7	.	.	1	1.7	35	58.3
	Age at diagnosis	1-4	3	2	66.7
		5-9	39	1	2.6	21	53.8
		10-14	108	8	7.4	3	2.8	.	.	64	59.3	.	.	5	4.6
		15-20	170	26	15.3	3	1.8	2	1.2	81	47.6	.	.	2	1.2

	Treatment	Chemotherapy, no radiation	251	31	12.4	3	1.2	.	.	139	55.4	.	.	6	2.4
		Chemotherapy and radiation	41	4	9.8	3	7.3	2	4.9	28	68.3	.	.	1	2.4
Females	All cases		318	34	10.7	4	1.3	1	0.3	156	49.1	.	.	9	2.8
	Age at baseline	<18	5	1	20.0	3	60.0
		18-19	10	1	10.0	6	60.0	.	.	1	10.0
		20-24	64	13	20.3	1	1.6	1	1.6	32	50.0	.	.	8	12.5
		25-29	78	11	14.1	1	1.3	.	.	31	39.7
		30-34	98	7	7.1	2	2.0	.	.	50	51.0
		35+	63	1	1.6	34	54.0
	Years since diagnosis	5-9	42	8	19.0	1	2.4	.	.	26	61.9	.	.	9	21.4
		10-14	96	18	18.8	.	.	1	1.0	32	33.3
		15-19	109	8	7.3	3	2.8	.	.	57	52.3
		20+	71	41	57.7
	Age at diagnosis	1-4	7	1	14.3	3	42.9
		5-9	33	3	9.1	17	51.5
		10-14	146	19	13.0	2	1.4	1	0.7	78	53.4	.	.	6	4.1
		15-20	132	11	8.3	2	1.5	.	.	58	43.9	.	.	3	2.3
	Treatment	Chemotherapy, no radiation	241	33	13.7	3	1.2	.	.	136	56.4	.	.	6	2.5
		Chemotherapy and radiation	33	1	3.0	1	3.0	1	3.0	20	60.6	.	.	3	9.1

CCSS data from February 2006 data freeze-all % based on denominator with non-missing values

Data for patients with medical records abstraction

Chemotherapy initiated more than 5 years post-diagnosis is not included.